VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PHRPhreesia, Inc.
$9.38$580M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

PHR logoPhreesia, Inc.(PHR)Earnings, Financials & Key Ratios

PHR•NYSE
250.1× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustryHealthcare ITSub-IndustryPatient Engagement, Intake and Payments
AboutPhreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.Show more
  • Revenue$481M+14.5%
  • EBITDA$25M+182.2%
  • Net Income$2M+103.9%
  • EPS (Diluted)0.04+103.7%
  • Gross Margin67.93%+0.1%
  • EBITDA Margin5.17%+171.8%
  • Operating Margin-1.38%+90.1%
  • Net Margin0.48%+103.4%
  • ROE0.77%+103.4%

PHR Key Insights

Phreesia, Inc. (PHR) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 26.4%

✗Weaknesses

  • ✗Weak momentum: RS Rating 19 (bottom 19%)
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when PHR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PHR Price & Volume

Phreesia, Inc. (PHR) stock price & volume — 10-year historical chart

Loading chart...

PHR Growth Metrics

Phreesia, Inc. (PHR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years26.45%
3 Years19.6%
TTM14.05%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM121.5%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-8.99%

Return on Capital

10 Years-29.3%
5 Years-31.15%
3 Years-24.33%
Last Year-1.75%

PHR Recent Earnings

Phreesia, Inc. (PHR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 27, 2026
Metric
Actual
Est
EPS
$0.05+150.0%
$0.02
Rev
$131M+0.7%
$130M
Q2 2026
Mar 30, 2026
Metric
Actual
Est
EPS
$0.12+82.6%
$0.07
Rev
$127M+0.2%
$127M
Q4 2025
Dec 8, 2025
Metric
Actual
Est
EPS
$0.10
$0.00
Rev
$120M+0.3%
$120M
Q4 2025
Sep 4, 2025
Metric
Actual
Est
EPS
$0.01+114.3%
$0.07
Rev
$117M-2.4%
$120M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 27, 2026
$0.05vs $0.02+150.0%
$131Mvs $130M+0.7%
Q2 2026Mar 30, 2026
$0.12vs $0.07+82.6%
$127Mvs $127M+0.2%
Q4 2025Dec 8, 2025
$0.10vs $0.00
$120Mvs $120M+0.3%
Q4 2025Sep 4, 2025
$0.01vs $0.07+114.3%
$117Mvs $120M-2.4%
Based on last 12 quarters of dataView full earnings history →

PHR Peer Comparison

Phreesia, Inc. (PHR) competitors in Patient Engagement, Intake and Payments — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
HCAT logoHCATHealth Catalyst, Inc.Direct Competitor128.58M1.74-0.681.48%-87.69%-99.78%0.70
DOCS logoDOCSDoximity, Inc.Direct Competitor3.83B20.4620.8813.05%30.4%19.36%0.01
GDRX logoGDRXGoodRx Holdings, Inc.Direct Competitor922.03M2.6631.180.57%3.74%4.75%0.10
VEEV logoVEEVVeeva Systems Inc.Product Competitor24.9B153.3028.1816.34%28.37%13.36%0.01
INVA logoINVAInnoviva, Inc.Supply Chain1.66B22.496.8218.52%118.91%47.59%0.23
TDOC logoTDOCTeladoc Health, Inc.Supply Chain1.46B8.07-7.08-1.54%-6.81%-12.37%0.75
AMWL logoAMWLAmerican Well CorporationSupply Chain140.85M8.43-1.41-1.98%-48.16%-33.48%0.02
PGNY logoPGNYProgyny, Inc.Supply Chain2.04B26.0840.1210.4%5.23%13.34%0.05

Compare PHR vs Peers

Phreesia, Inc. (PHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HCAT

Most directly comparable listed peer for PHR.

Scale Benchmark

vs VEEV

Larger-name benchmark to compare PHR against a more recognizable public peer.

Peer Set

Compare Top 5

vs HCAT, DOCS, GDRX, VEEV

PHR Income Statement

Phreesia, Inc. (PHR) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricJan'18Jan'19Jan'20Jan'21Jan'22Jan'23Jan'24Jan'25Jan'26TTM
Sales/Revenue
79.83M99.89M124.78M148.68M213.23M280.91M356.3M419.81M480.59M495.59M
Revenue Growth %
-25.12%24.92%19.15%43.42%31.74%26.84%17.83%14.48%14.05%
Cost of Goods Sold
29.77M37M44.72M52.39M81.39M109.27M124.01M134.93M154.12M169.46M
COGS % of Revenue
37.29%37.04%35.84%35.23%38.17%38.9%34.81%32.14%32.07%-
Gross Profit
50.06M▲ 0%
62.89M▲ 25.6%
80.06M▲ 27.3%
96.29M▲ 20.3%
131.84M▲ 36.9%
171.64M▲ 30.2%
232.29M▲ 35.3%
284.88M▲ 22.6%
326.47M▲ 14.6%
326.13M▲ 0%
Gross Margin %
62.71%62.96%64.16%64.77%61.83%61.1%65.19%67.86%67.93%65.81%
Gross Profit Growth %
-25.62%27.3%20.27%36.92%30.19%35.33%22.64%14.6%-
Operating Expenses
64.62M72.39M95.36M121.96M248.66M348.19M368.77M342.98M333.08M322.49M
OpEx % of Revenue
80.94%72.47%76.42%82.03%116.62%123.95%103.5%81.7%69.31%-
Selling, General & Admin
43.6M46.44M62.81M83.43M175.09M231.65M226.93M197.73M180.15M180.26M
SG&A % of Revenue
54.61%46.49%50.34%56.12%82.11%82.46%63.69%47.1%37.48%-
Research & Development
11.38M14.35M18.62M22.62M52.27M91.24M112.35M117.36M121.48M117.98M
R&D % of Revenue
14.25%14.37%14.92%15.22%24.51%32.48%31.53%27.96%25.28%-
Other Operating Expenses
9.64M11.59M13.92M15.91M21.3M25.3M29.49M27.89M31.45M2.67M
Operating Income
-14.55M▲ 0%
-9.49M▲ 34.8%
-15.3M▼ 61.1%
-25.67M▼ 67.8%
-116.82M▼ 355.1%
-176.55M▼ 51.1%
-136.48M▲ 22.7%
-58.1M▲ 57.4%
-6.61M▲ 88.6%
3.64M▲ 0%
Operating Margin %
-18.23%-9.5%-12.26%-17.27%-54.78%-62.85%-38.3%-13.84%-1.38%0.73%
Operating Income Growth %
-34.76%-61.14%-67.81%-355.05%-51.14%22.7%57.43%88.62%-
EBITDA
-3.52M2.1M-1.37M-7.74M-92.3M-147.78M-105.94M-30.21M24.84M38.29M
EBITDA Margin %
-4.41%2.1%-1.1%-5.2%-43.29%-52.61%-29.73%-7.2%5.17%7.73%
EBITDA Growth %
-159.61%-165.42%-463.17%-1092.81%-60.11%28.32%71.48%182.22%382.1%
D&A (Non-Cash Add-back)
11.03M11.59M13.92M17.93M24.52M28.77M30.54M27.89M31.45M34.65M
EBIT
-14.55M-9.49M-19.03M-25.55M-116.82M-174.25M-133.49M-53.46M-1.99M7.72M
Net Interest Income
-3.64M-3.5M-2.44M-1.57M-1.08M1.06M2.21M330K-4.78M-6.55M
Interest Income
401185598K122K79K2.48M4.07M2.68M2.17M2.77M
Interest Expense
3.64M3.5M3.04M1.7M1.16M1.41M1.85M2.35M6.95M9.32M
Other Income/Expense
-3.64M-5.57M-6.78M-1.57M-1.16M889K1.14M2.29M-2.33M-4.68M
Pretax Income
-18.19M▲ 0%
-15.06M▲ 17.2%
-22.07M▼ 46.5%
-27.24M▼ 23.4%
-117.98M▼ 333.1%
-175.66M▼ 48.9%
-135.34M▲ 23.0%
-55.81M▲ 58.8%
-8.94M▲ 84.0%
-1.04M▲ 0%
Pretax Margin %
-22.79%-15.08%-17.69%-18.32%-55.33%-62.53%-37.99%-13.29%-1.86%-0.21%
Income Tax
0-2.06M-1.78M49K182K483K1.54M2.72M-11.25M-10.22M
Effective Tax Rate %
0%13.7%8.06%-0.18%-0.15%-0.27%-1.14%-4.87%125.79%984.68%
Net Income
-18.19M▲ 0%
-15.06M▲ 17.2%
-20.29M▼ 34.7%
-27.29M▼ 34.5%
-118.16M▼ 333.0%
-176.15M▼ 49.1%
-136.88M▲ 22.3%
-58.53M▲ 57.2%
2.31M▲ 103.9%
9.18M▲ 0%
Net Margin %
-22.79%-15.08%-16.26%-18.36%-55.41%-62.71%-38.42%-13.94%0.48%1.85%
Net Income Growth %
-17.21%-34.73%-34.49%-332.95%-49.07%22.29%57.24%103.94%121.5%
Net Income (Continuing)
-18.19M-15.06M-20.29M-27.29M-118.16M-176.15M-136.88M-58.53M2.31M9.18M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-11.82▲ 0%
-8.16▲ 31.0%
-1.00▲ 87.7%
-0.69▲ 31.0%
-2.37▼ 243.5%
-3.36▼ 41.8%
-2.51▲ 25.3%
-1.02▲ 59.4%
0.04▲ 103.7%
0.15▲ 0%
EPS Growth %
-30.96%87.75%31%-243.48%-41.77%25.3%59.36%103.68%-8.99%
EPS (Basic)
-11.82-8.16-1.00-0.69-2.37-3.36-2.51-1.020.04-
Diluted Shares Outstanding
1.54M1.84M20.3M39.52M49.89M52.44M54.56M57.59M61.49M62.04M
Basic Shares Outstanding
1.54M1.84M20.3M39.52M49.89M52.44M54.56M57.59M59.74M60.94M
Dividend Payout Ratio
----------

PHR Balance Sheet

Phreesia, Inc. (PHR) balance sheet — assets, liabilities & shareholders' equity

MetricJan'18Jan'19Jan'20Jan'21Jan'22Jan'23Jan'24Jan'25Jan'26TTM
Total Current Assets
35.95M32.88M131.54M272.27M386.35M262.44M195.68M203.28M279.84M267.26M
Cash & Short-Term Investments
10.5M1.54M90.31M218.78M313.81M176.68M87.52M84.22M73.83M74.71M
Cash Only
10.5M1.54M90.31M218.78M313.81M176.68M87.52M84.22M73.83M74.71M
Short-Term Investments
0000000000
Accounts Receivable
12.31M26.29M21.98M29.05M40.26M51.39M64.86M73.62M154.63M143.31M
Days Sales Outstanding
56.2896.0764.2971.3268.9266.7866.4564.01117.4485.25
Inventory
1.64M1.67M6.88M8.95M1.64M1.06M768K000
Days Inventory Outstanding
20.116.556.1362.347.363.532.26---
Other Current Assets
8.68M1.67M13.26M15.49M21.74M25.94M32.48M34.13M51.39M49.25M
Total Non-Current Assets
21.18M26.38M27.22M54.4M108.13M107.62M174.64M185.13M383.95M398.88M
Property, Plant & Equipment
13.17M14.21M14.49M29.31M36.98M22.24M17.17M25.13M23.59M23.4M
Fixed Asset Turnover
6.06x7.03x8.61x5.07x5.77x12.63x20.75x16.71x20.37x21.00x
Goodwill
0250.19K250K8.31M33.62M33.74M75.84M75.84M170.06M169.51M
Intangible Assets
6.72M9.25M9.93M13.2M30.41M46.55M77.76M80.91M79.76M77.15M
Long-Term Investments
81.87K01.59M1.25M2.44M000066.15M
Other Non-Current Assets
1.3M2.67M180K1.67M4.16M5.01M3.87M3.25M108.94M61.08M
Total Assets
57.14M▲ 0%
59.26M▲ 3.7%
158.76M▲ 167.9%
326.67M▲ 105.8%
494.48M▲ 51.4%
370.06M▼ 25.2%
370.33M▲ 0.1%
388.42M▲ 4.9%
663.79M▲ 70.9%
666.14M▲ 0%
Asset Turnover
1.40x1.69x0.79x0.46x0.43x0.76x0.96x1.08x0.72x0.92x
Asset Growth %
-3.72%167.89%105.76%51.37%-25.16%0.07%4.88%70.9%162.79%
Total Current Liabilities
24.98M27.93M35.35M54.99M68.43M79.04M110.12M114.02M183.24M152.11M
Accounts Payable
2.2M3.75M6.02M4.39M5.12M10.84M8.48M5.62M11.48M11.89M
Days Payables Outstanding
273749.1130.5822.9636.224.9615.2127.1819.45
Short-Term Debt
1.17M97K2.32M4.86M221K246K1.1M1.22M2.66M6.36M
Deferred Revenue (Current)
4.89M6.49M5.4M10.84M16.49M17.69M24.11M32.76M49.52M145.71M
Other Current Liabilities
8.68M10.22M16.58M24.87M26.84M32.57M53.16M844K72.29M94.29M
Current Ratio
1.44x1.18x3.72x4.95x5.65x3.32x1.78x1.78x1.53x1.76x
Quick Ratio
1.37x1.12x3.53x4.79x5.62x3.31x1.77x1.78x1.53x1.76x
Cash Conversion Cycle
49.3775.5771.31103.0853.3234.1143.75--65.81
Total Non-Current Liabilities
199.84M242.31M21.54M8.37M8.76M3.2M8.76M9.58M143.34M154.94M
Long-Term Debt
19.45M27.92M21.54M6.47M139K2.73M2.05M719K90M85.3M
Capital Lease Obligations
652.41K2.4M2.1M1.9M8.56M3.07M3.48M8.08M3.22M4.93M
Deferred Tax Liabilities
000000270K484K4.5M10.43M
Other Non-Current Liabilities
179.73M211.99M-2.1M00-2.73M2.86M185K45.62M64.12M
Total Liabilities
224.82M270.24M56.89M63.36M77.2M82.24M118.88M123.61M326.58M307.05M
Total Debt
22.93M32.29M23.86M14.32M15.8M9.18M11.98M17.8M102.45M92.56M
Net Debt
12.43M30.74M-66.45M-204.46M-298.01M-167.5M-75.54M-66.42M28.62M17.85M
Debt / Equity
--0.23x0.05x0.04x0.03x0.05x0.07x0.30x0.26x
Debt / EBITDA
-15.37x------4.12x2.42x
Net Debt / EBITDA
-14.64x------1.15x0.47x
Interest Coverage
-4.00x-2.71x-6.25x-15.07x-100.44x-123.50x-72.00x-22.78x-0.29x0.83x
Total Equity
-167.68M▲ 0%
-210.97M▼ 25.8%
101.86M▲ 148.3%
263.31M▲ 158.5%
417.28M▲ 58.5%
287.82M▼ 31.0%
251.45M▼ 12.6%
264.81M▲ 5.3%
337.21M▲ 27.3%
359.09M▲ 0%
Equity Growth %
--25.82%148.28%158.49%58.48%-31.03%-12.64%5.31%27.34%98.98%
Book Value per Share
-108.98-114.355.026.668.365.494.614.605.485.79
Total Shareholders' Equity
-167.68M-210.97M101.86M263.31M417.28M287.82M251.45M264.81M337.21M359.09M
Common Stock
16.38K19.95K366K449K521K542K577K601K620K632K
Retained Earnings
-167.7M-210.99M-284.49M-311.78M-429.94M-606.08M-742.97M-801.5M-799.19M-796.23M
Treasury Stock
00-399K-4.96M-13.96M-33.6M-45.52M-45.52M-45.52M-46.62M
Accumulated OCI
-20.33M-27.86M-158.76M0000-51K-382K-571K
Minority Interest
0000000000

PHR Cash Flow Statement

Phreesia, Inc. (PHR) cash flow — operating, investing & free cash flow history

MetricJan'18Jan'19Jan'20Jan'21Jan'22Jan'23Jan'24Jan'25Jan'26TTM
Cash from Operations
-11.14M-2.13M826K2.89M-74.71M-90.12M-32.38M32.38M78.81M86.04M
Operating CF Margin %
-13.96%-2.13%0.66%1.94%-35.04%-32.08%-9.09%7.71%16.4%-
Operating CF Growth %
-80.88%138.78%249.88%-2685.12%-20.63%64.07%200.01%143.4%357.2%
Net Income
-18.19M-15.06M-20.29M-27.29M-118.16M-176.15M-136.88M-58.53M2.31M9.18M
Depreciation & Amortization
9.64M11.59M13.92M15.91M21.3M25.3M29.49M27.89M31.45M34.53M
Stock-Based Compensation
805K1.45M6.18M13.49M36.14M58.77M71.7M66.97M67.45M63.78M
Deferred Taxes
598K2.06M-775K-65K143K434K228K214K-13.27M-12.68M
Other Non-Cash Items
2.29M1.38M7.54M4.94M4.43M5.37M4.73M2.33M4.96M1.37M
Working Capital Changes
-6.29M-3.55M-5.75M-4.09M-18.57M-3.86M-1.64M-6.49M-14.09M-11.16M
Change in Receivables
-3.38M-3.8M-5.91M-6.62M-10.22M-11.13M-11.21M-8.81M-10.15M6.91M
Change in Inventory
1.65M-2.45M3.37M2.62M000000
Change in Payables
-2.06M1.96M-30K-3.82M2.88M4.77M-1.99M-3.23M5.26M7.16M
Cash from Investing
-11.96M-11.02M-12.32M-25.09M-65.23M-26.2M-39.67M-24.09M-161.88M-149.69M
Capital Expenditures
-11.96M-9.83M-12.32M-18.57M-30.8M-26.2M-5.81M-8.71M-11.1M-11.91M
CapEx % of Revenue
14.99%9.84%9.87%12.49%14.45%9.33%1.63%2.07%2.31%2.4%
Acquisitions
0-1.19M0-6.51M-34.42M0-14.57M0-153.19M-153.19M
Investments
----------
Other Investing
-5.38M-5.11M-5.3M000-19.29M-15.38M-13.3M-12.65M
Cash from Financing
31.29M4.19M100.27M150.66M234.97M-20.8M-17.11M-11.49M72.85M49.45M
Debt Issued (Net)
-1.1M4.03M-11.15M-25.21M-4.27M-5.95M-6.78M-7.81M83.17M75.19M
Equity Issued (Net)
32.46M0130.78M169.84M236.82M-14.46M-12.18M3.93M3.83M3.58M
Dividends Paid
00-14.96M0000000
Share Repurchases
000-4.96M-8.99M-19.38M-12.18M000
Other Financing
-77K165.63K-4.41M6.04M2.42M-397K1.84M-7.61M-14.15M-29.33M
Net Change in Cash
8.18M▲ 0%
-8.96M▼ 209.5%
88.77M▲ 1090.7%
128.47M▲ 44.7%
95.03M▼ 26.0%
-137.13M▼ 244.3%
-89.16M▲ 35.0%
-3.3M▲ 96.3%
-10.39M▼ 214.8%
-16.16M▲ 0%
Free Cash Flow
-23.11M▲ 0%
-11.96M▲ 48.2%
-11.49M▲ 3.9%
-15.69M▼ 36.5%
-105.52M▼ 572.7%
-116.33M▼ 10.2%
-57.48M▲ 50.6%
8.29M▲ 114.4%
67.71M▲ 716.6%
73.72M▲ 0%
FCF Margin %
-28.94%-11.98%-9.21%-10.55%-49.48%-41.41%-16.13%1.98%14.09%14.88%
FCF Growth %
-48.23%3.92%-36.46%-572.71%-10.25%50.59%114.43%716.61%189.29%
FCF per Share
-15.02-6.48-0.57-0.40-2.12-2.22-1.050.141.101.19
FCF Conversion (FCF/Net Income)
0.61x0.14x-0.04x-0.11x0.63x0.51x0.24x-0.55x34.18x8.03x
Interest Paid
0001.47M802K763K1.31M2.19M1.61M5.14M
Taxes Paid
00064K49K39K37K3.07M1.9M2.53M

PHR Key Ratios

Phreesia, Inc. (PHR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric20192020202120222023202420252026TTM
Return on Equity (ROE)
--19.92%-14.95%-34.72%-49.96%-50.77%-22.67%0.77%2.79%
Return on Invested Capital (ROIC)
--32.4%-40.85%-98.38%-110.54%-69.11%-23.28%-1.76%0.93%
Gross Margin
62.96%64.16%64.77%61.83%61.1%65.19%67.86%67.93%65.81%
Net Margin
-15.08%-16.26%-18.36%-55.41%-62.71%-38.42%-13.94%0.48%1.85%
Debt / Equity
-0.23x0.05x0.04x0.03x0.05x0.07x0.30x0.26x
Interest Coverage
-2.71x-6.25x-15.07x-100.44x-123.50x-72.00x-22.78x-0.29x0.83x
FCF Conversion
0.14x-0.04x-0.11x0.63x0.51x0.24x-0.55x34.18x8.03x
Revenue Growth
25.12%24.92%19.15%43.42%31.74%26.84%17.83%14.48%14.05%
Related:PHR Dividend History·PHR Revenue History·PHR Price History·PHR P/E History·PHR Financial Ratios·PHR Institutional Holders

PHR SEC Filings & Documents

Phreesia, Inc. (PHR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 27, 2026·SEC

Material company update

May 11, 2026·SEC

Material company update

May 4, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 13, 2025·SEC

10-Q Quarterly Reports

4
FY 2026

May 28, 2026·SEC

FY 2025

Dec 9, 2025·SEC

FY 2025

Sep 5, 2025·SEC

PHR Frequently Asked Questions

Phreesia, Inc. (PHR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Phreesia, Inc. (PHR) reported $495.6M in revenue for fiscal year 2026. This represents a 521% increase from $79.8M in 2018.

Phreesia, Inc. (PHR) grew revenue by 14.5% over the past year. This is steady growth.

Yes, Phreesia, Inc. (PHR) is profitable, generating $9.2M in net income for fiscal year 2026 (0.5% net margin).

Dividend & Returns

Phreesia, Inc. (PHR) has a return on equity (ROE) of 0.8%. This is below average, suggesting room for improvement.

Phreesia, Inc. (PHR) generated $73.7M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in PHR back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

How much would $100/month in PHR be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →